Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cellebrite DI Ltd (CLBT) Q4 2024 Earnings Call Highlights: Strong ARR Growth and Strategic ...

In This Article:

  • Annual Recurring Revenue (ARR): Grew 25% year-over-year to $396 million.

  • Free Cash Flow: $122 million for the full year 2024.

  • Adjusted EBITDA Margin: 25% for the full year 2024.

  • Revenue: $401.2 million for the full year 2024, a 23% increase from the previous year.

  • Gross Margin: 85% for the full year 2024, up from 84.2% in 2023.

  • Net Income: Non-GAAP net income of $97.8 million for 2024.

  • Cash Position: Ended 2024 with $483.8 million in cash, cash equivalents, and investments.

  • Operating Expenses: $65.1 million in Q4, a 13% year-over-year increase.

  • Subscription Software Revenue: Increased by 26% for the full year 2024.

  • Guardian ARR Growth: Triple-digit percentage growth year-over-year in the second half of 2024.

  • Pathfinder ARR Growth: Year-on-year ARR expansion in the 35% to 50% range.

  • Cloud-based ARR: Nearly doubled to 17% of total ARR in 2024.

  • 2025 ARR Outlook: Expected to range from $480 million to $495 million, a 21% to 25% increase over 2024.

  • 2025 Revenue Outlook: Expected to range from $480 million to $490 million, a 20% to 22% growth over 2024.

  • 2025 Adjusted EBITDA Outlook: Expected to range from $113 million to $123 million, or 24% to 25% of total revenue.

Release Date: February 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Cellebrite DI Ltd (NASDAQ:CLBT) exceeded its original revenue and adjusted EBITDA targets for 2024, delivering at the higher end of ARR expectations.

  • The company achieved a Rule of 50 performance with 25% ARR growth and 25% adjusted EBITDA margins.

  • Cellebrite DI Ltd (NASDAQ:CLBT) generated $122 million in free cash flow in 2024, showcasing strong cash generation.

  • The company reported significant growth in its Guardian and Pathfinder solutions, with Guardian ARR generating triple-digit percentage growth year-over-year.

  • Cellebrite DI Ltd (NASDAQ:CLBT) achieved FedRAMP ready status, enhancing its potential to expand within the US federal sector.

Negative Points

  • The CEO search is ongoing, with no specific timeline for the appointment of a new leader.

  • There are modest headwinds due to geopolitical changes and regime disruptions in the US and Europe.

  • The company faces challenges in expanding its customer base in certain countries, impacting growth retention rates.

  • Cellebrite DI Ltd (NASDAQ:CLBT) anticipates a modest impact on Q1 2025 results due to decisions to exit certain countries.

  • The magnitude of the EBITDA beat in Q4 2024 was lower than in previous quarters, with guidance for Q1 2025 in line with expectations.